Diphtheria – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diphtheria – Pipeline Review, H2 2017’, provides an overview of the Diphtheria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diphtheria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diphtheria

The report reviews pipeline therapeutics for Diphtheria by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diphtheria therapeutics and enlists all their major and minor projects

The report assesses Diphtheria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diphtheria

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diphtheria

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

Daiichi Sankyo Co Ltd

GlaxoSmithKline Plc

Green Cross Corp

Indian Immunologicals Ltd

Kaketsuken

LG Chem Ltd

Sanofi

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diphtheria - Overview 8

Diphtheria - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Diphtheria - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Diphtheria - Companies Involved in Therapeutics Development 21

Beijing Minhai Biotechnology Co Ltd 21

Biological E Ltd 21

Cadila Healthcare Ltd 21

Daiichi Sankyo Co Ltd 22

GlaxoSmithKline Plc 22

Green Cross Corp 23

Indian Immunologicals Ltd 24

Kaketsuken 24

LG Chem Ltd 24

Sanofi 25

Sanofi Pasteur SA 25

Serum Institute of India Ltd 26

Shantha Biotechnics Pvt Ltd 26

Diphtheria - Drug Profiles 28

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

BK-1310 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

DTaP-IPV-HB-PRPT - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

GC-3111A - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

KD-370 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

LBVD - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VN-0105 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Diphtheria - Dormant Projects 58

Diphtheria - Discontinued Products 61

Diphtheria - Product Development Milestones 62

Featured News & Press Releases 62

Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5 62

Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA 62

Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India 62

May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization 63

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

List of Tables

Number of Products under Development for Diphtheria, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Number of Products under Development by Universities/Institutes, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Products under Development by Universities/Institutes, H2 2017 14

Number of Products by Stage and Target, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Diphtheria – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 21

Diphtheria – Pipeline by Biological E Ltd, H2 2017 21

Diphtheria – Pipeline by Cadila Healthcare Ltd, H2 2017 22

Diphtheria – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 22

Diphtheria – Pipeline by GlaxoSmithKline Plc, H2 2017 23

Diphtheria – Pipeline by Green Cross Corp, H2 2017 23

Diphtheria – Pipeline by Indian Immunologicals Ltd, H2 2017 24

Diphtheria – Pipeline by Kaketsuken, H2 2017 24

Diphtheria – Pipeline by LG Chem Ltd, H2 2017 25

Diphtheria – Pipeline by Sanofi, H2 2017 25

Diphtheria – Pipeline by Sanofi Pasteur SA, H2 2017 26

Diphtheria – Pipeline by Serum Institute of India Ltd, H2 2017 26

Diphtheria – Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017 27

Diphtheria – Dormant Projects, H2 2017 58

Diphtheria – Dormant Projects, H2 2017 (Contd..1), H2 2017 60

Diphtheria – Discontinued Products, H2 2017 61

List of Figures

List of Figures

Number of Products under Development for Diphtheria, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Number of Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Targets, H2 2017 15

Number of Products by Stage and Targets, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports